Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 4Active not recruiting 2Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1

Conditions

Smoldering Multiple Myeloma 1Prostatic Neoplasms 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1

Interventions

pembrolizumab 68Cyclophosphamide 46Cisplatin 43Nivolumab 36Paclitaxel 33Carboplatin 31Radiotherapy 29Gemcitabine 28Docetaxel 25Dexamethasone 22atezolizumab 21Bevacizumab 20Doxorubicin 19Magnetic Resonance Spectroscopy 18Blood Specimen Collection 18Radiosurgery 17fludarabine 16Vincristine 16Lenalidomide 16Etoposide 16Letrozole 15Ipilimumab 15Fluorouracil 15palbociclib 14Surveys and Questionnaires 14Rituximab 14Radiation 14Leucovorin 14Cytarabine 14durvalumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Curcumin × 90 days × Clear all
NCT04731844 2026-05-12

Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer

University of Rochester

Phase 2 Completed
30 enrolled 13 charts
GenitourinaryPlasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡